Prominent Scientist Joins Peregrine Pharmaceuticals' Scientific Resource Board

Peregrine Pharmaceuticals Adds Two Prominent Virologists to Its Scientific Resource Board

Peregrine Receives FDA Approval to Proceed With Tarvacin(TM) Phase I Study

Peregrine Gains Access to Merck KGaA's Protein Expression Technology

Peregrine and New Approaches to Brain Tumor Therapy (NABTT) Consortium Receive Approval for Cotara(R) Brain Cancer Protocol

Peregrine Announces Second Quarter Financial Results

Peregrine Pharmaceuticals and New Approaches to Brain Tumor Therapy (NABTT) Consortium Enter Collaboration to Treat Brain Cancer Patients

Tarvacin(TM) Equivalent Plus Radiation Therapy Reduces Tumor Growth by 98%

Peregrine Pharmaceuticals and Affitech AS Expand Collaboration to Develop Up to Six New Fully Human Antibodies

Peregrine Pharmaceuticals Provides Tarvacin(TM) IND Update